| Genesis Clinical Health Group, Inc | |
|
225 Calle Caribe 225 Caribe St Arroyo PR 00714-3056 | |
| (787) 989-2447 | |
| Not Available |
| Full Name | Genesis Clinical Health Group, Inc |
|---|---|
| Speciality | Clinic/center - Adult Mental Health |
| Location | 225 Calle Caribe, Arroyo, Puerto Rico |
| Authorized Official Name and Position | Marisela Torres (PRESIDENTA) |
| Authorized Official Contact | 7879892447 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Genesis Clinical Health Group, Inc 225 Calle Caribe Urb Arroyo Del Mar Arroyo PR 00714-3056 Ph: (787) 989-2447 | Genesis Clinical Health Group, Inc 225 Calle Caribe 225 Caribe St Arroyo PR 00714-3056 Ph: (787) 989-2447 |
| NPI Number | 1881049294 |
|---|---|
| Provider Enumeration Date | 05/04/2016 |
| Last Update Date | 05/25/2016 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881049294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0850X | Clinic/center - Adult Mental Health | (* (Not Available)) | Primary |
News Archive
Rodents infected with a common parasite lose their fear of cats, resulting in easy meals for the felines. Now IU School of Medicine researchers have identified a new way the parasite may modify brain cells, possibly helping explain changes in the behavior of mice - and humans.
ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).
Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
Roche, OrbiMed, and McKinsey announced fifteen finalists of the SEED Competition at the SEED Finalist Coaching Day event in Shanghai's Zhangjiang Hi-Tech Park on March 2, 2010. The event was managed and presented by ChinaBio® Accelerator. The finalists will go on to compete for the grand prize of RMB 300,000 to be presented at the SEED Final Competition and Award Ceremony in Shanghai on April 23, 2010.
› Verified 4 days ago